Clinical trial
Efficacy, Safety, and PKPD Study of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis (gMG): an Open-label, Randomized Controlled Trial
NCT06827587 is registered in ClinicalTrials.gov with First Affiliated Hospital of Wenzhou Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety, and PKPD Study of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis (gMG): an Open-label, Randomized Controlled Trial
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical University
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- February 28, 2025
- Completion date
- December 31, 2026
- Enrollment
- 60 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.